Glycomine Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$115M
- Investors
-
22
Glycomine General Information
Description
Developer of orphan drugs designed to treat rare disorders of metabolism and protein misfolding. The company's drugs combine replacement therapies such as substrates, enzymes, and proteins with intracellular delivery vehicles consisting of bio-nano materials and ligands that target the molecules to the cell interior of clinically relevant organs, enabling physicians to efficiently treat their patients.
Contact Information
Website
www.glycomine.comCorporate Office
- MBC BioLabs
- 733 Industrial Road
- San Carlos, CA 94070
- United States
Corporate Office
- MBC BioLabs
- 733 Industrial Road
- San Carlos, CA 94070
- United States
Glycomine Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series C) | 14-May-2026 | $115M | Completed | Clinical Trials - Phase 2 | ||
| 4. Later Stage VC (Series B) | 11-Jun-2021 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series A) | 16-Nov-2016 | Completed | Clinical Trials - Phase 1 | |||
| 2. Accelerator/Incubator | 01-Jan-2016 | $630K | $630K | Completed | Clinical Trials - Phase 1 | |
| 1. Accelerator/Incubator | 11-Mar-2015 | Completed | Pre-Clinical Trials |
Glycomine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B-2 | ||||||||
| Series B-1 | 61,114,556 | $0.000100 | $0.67 | $0.67 | 1x | $0.67 | 16.67% | |
| Series A | 1,337,056 | $0.000100 | $3.8 | $3.8 | 1x | $3.8 | 0.36% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Glycomine Comparisons
Industry
Financing
Details
Glycomine Competitors (52)
One of Glycomine’s 52 competitors is Cognition Therapeutics, a Formerly VC-backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cognition Therapeutics | Formerly VC-backed | New York, NY | ||||
| MnPharm | Venture Capital-Backed | White Bear Lake, MN | ||||
| Regenerx | Formerly VC-backed | Rockville, MD | ||||
| Carisma Therapeutics | Formerly VC-backed | Philadelphia, PA | ||||
| MiNA Therapeutics | Venture Capital-Backed | London, United Kingdom |
Glycomine Patents
Glycomine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026226709-A1 | Mrna therapy for pmm2 | Pending | 24-Apr-2025 | ||
| AU-2025230053-A1 | Liposomal formulations, and methods of using and preparing thereof | Pending | 29-Feb-2024 | ||
| WO-2025184398-A1 | Liposomal formulations, and methods of using and preparing thereof | Pending | 29-Feb-2024 | ||
| AU-2025228129-A1 | Methods of treating congenital disorders of glycosylation (cdg) and ataxia in subjects suffering from cdg | Pending | 29-Feb-2024 | ||
| WO-2025184395-A1 | Methods of treating congenital disorders of glycosylation (cdg) and ataxia in subjects suffering from cdg | Pending | 29-Feb-2024 | A61P25/00 |
Glycomine Signals
Glycomine Investors (22)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aberdeen Investments (Scotland) | Asset Manager | Minority | ||
| Advent Life Sciences | Venture Capital | Minority | ||
| CTI Life Sciences Fund | Venture Capital | Minority | ||
| Tekla World Healthcare Fund | Asset Manager | Minority | ||
| Abingworth | Venture Capital | Minority |
Glycomine FAQs
-
When was Glycomine founded?
Glycomine was founded in 2015.
-
Where is Glycomine headquartered?
Glycomine is headquartered in San Carlos, CA.
-
What is the size of Glycomine?
Glycomine has 20 total employees.
-
What industry is Glycomine in?
Glycomine’s primary industry is Drug Discovery.
-
Is Glycomine a private or public company?
Glycomine is a Private company.
-
What is the current valuation of Glycomine?
The current valuation of Glycomine is .
-
What is Glycomine’s current revenue?
The current revenue for Glycomine is .
-
How much funding has Glycomine raised over time?
Glycomine has raised $196M.
-
Who are Glycomine’s investors?
Aberdeen Investments (Scotland), Advent Life Sciences, CTI Life Sciences Fund, Tekla World Healthcare Fund, and Abingworth are 5 of 22 investors who have invested in Glycomine.
-
Who are Glycomine’s competitors?
Cognition Therapeutics, MnPharm, Regenerx, Carisma Therapeutics, and MiNA Therapeutics are some of the 52 competitors of Glycomine.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process